Prévention des risques d’infertilité liés aux traitements antitumoraux dans le cancer du testicule
Tóm tắt
Từ khóa
Tài liệu tham khảo
AUROUX M.R., DULIOUST E.M., NAWAR N.Y. et al.: Antimotic drugs in the male rat: behavorial abnormalities in the second generation. J. Androl., 1988, 9: 153.
BUJAN L., BACHAUD J.M., CHEVREAU C. et al.: Traitement du cancer du testicule et protection de la spermatogénèse. Contracept. Fertil. Sex., 1996, 24: 596–602.
COLEMAN M.P., ESTEVE J., ARSLAN A., RENARD H.: Trends in cancer incidence and mortality. International Agency for Research on Cancer. IARC scientific publications, 1993, 121: 521–542.
CZYGLIK F, AUGER J., ALBERT M., DAVID G.: L’autoconservation du sperme avant thérapeutique stérilisante. Nouv. Presse Med., 1982, 11: 2749–2752.
CZYGLIK F., KUNTSMANN J.M., JOUANNET P.: Autoconservation du sperme et préservation de la fertilité des hommes stérilisés. In: Englert Y., Guérin J.F., Jouannet P. eds. Stérilité masculine et procréation médicalement assistée. Paris, Doin, 1989 113
DAMEWOOD M.D., GROCHOW L.B.: Prospects for fertility after chemotherapy or radiation for neoplastic disease. Fertil. Steril., 1986, 45: 443
DAVID G., CZYGLIK F.: Les risques radiothérapiques et chimothérapiques à l’égard de la fonction de reproduction. In: Tubiana M. et Chassagne D. eds. Les risques de la radiothérapie et de la chimiothérapie en cancérologie. Paris, Masson, 1985: 98
DAVID G., CZYGLIK F.: Tolérance à la congélation du sperme humain en fonction de la qualité initiale du sperme. J. Gynecol. Obstet. Biol. Reprod., 1977, 6: 601
ES SLAMI S., CHARCELLAY S., PINON-LATAILLADE G., SOUFIR J.C.: Short term pretreatment with medroxyprogesterone and testosterone may potentiate irradiation damage to spermatogenesis in rats. Cancer, 1999, 15: 1313–1322.
FEDERATION CEOS, JOUANNET P., AUGER J.: L’incidence du cancer du testicule augmente-t-elle en France? Nouv. Presse Med., 1995, 24: 1133.
FOSSA S.D., AABYHOLM T., VESPESTAD S., NORMAN N., OUS S.: Semen quality after treatment for testicular cancer. Europ. Urol. 1993, 23: 172–176.
FRIED P., STEINFELD R., CASILETH B., STEINFELD A.: Incidence of developmental handicaps among offspring of men treated for testicular seminoma. Int. J. Androl., 1987, 10: 385
HARAPANHALLI R.S., NARRA V.R., YAGHMAI et al.: Vitamins as radioprotectors in vivo. II. Protection by vitamin A and soybean oil against radiation damage caused by internal radionucides. Radiat. Res., 1994, 139: 115–122.
KANGASNIEMI M., DODGE K., PEMBERTON A.E. et al.: Suppression of mouse spermatogenesis by a gonadotropin-releasing hormone antagonist and antiandrogen: failure to protect against radiationinduced gonadal damage. Endocrinology, 1996, 137: 949–955.
KRISHNAMURTHY H., JAGETIA G.C., JYOTHI P.: Radioprotective effect of zinc aspartate on mouse spermatogenesis: a flow cytometric evaluation. Mutat. Res., 1998, 401: 111–120.
KURDOGLU B., WILSON G., PARCHURI N., MEISTRICH M.L.: Protection from radiation-induced damage to spermatogenesis by hormone treatment. Radiat. Res., 1994, 139: 97–102.
MANABE F., TAKESHIMA H., AKAZA H.: Protecting spermatogenesis from damage induced by doxorubicin using the luteinizing hormone-releasing hormone agonist leuprorelin: an image analysis study of a rat experimental model. Cancer, 1997, 7: 1014–1021.
MEISTRICH M.L.: Potential genetic risks of using semen collected during chemotherapy. Hum. Reprod., 1993, 8: 8
MEISTRICH M.L., VAN BEEK M.E.: Radiation sensitivity of the human testis. Advances Radiat. Biol., 1990, 14: 227–268.
MEISTRICH M.L., WILSON G., YE W.S. et al.: Relationship among hormonal treatments, suppression of spermatogenesis, and testicular protection from chemotherapy-induced damage. Endocrinology, 1996, 137: 3823–3831.
MORRIS I.D., Bardin C.W., GUNSALUS G., WARD J.A.: Prolonged suppression of spermatogenesis by oestrogen does not preserve the seminiferous epithelium in procarbazine-treated rats. Int. J. Androl., 1990, 13: 180–189.
NONOMURA M, OKADA K, HIDA S, YOSHIDA O.: Does a gonadotropin-releasing hormone analogue prevent cisplatin-induced spermatogenetic impairment? An experimental study in the mouse. Urol. Res., 1991, 19: 135–140.
OATES R.D., SARAZEN A.A., KRANE R.J.: Preservation of fertility in patients with testicular carcinoma. World J. Urol., 1992, 10: 52
PETERSEN P.M., SKAKKEBAEK N.E., VISTISEN K. et al.: Semen quality and reproductive hormones before orchidectomy in men with testicular cancer. J. Clin. Oncol., 1999, 17: 941–947.
REVIDI P.: Aspects psychologiques de l’autoconservation du sperme dans les maladies graves. Contracept. Fertil. Sex., 1989, 17: 623
ROWLEY M.J., LEACE D.R., WARNER G.A., HELLER C.G.: Effect of graded doses of ionizing radiation on human testis. Radiat. Res., 1974, 59: 665
SANGER W.G., OLSON J.H., SHERMAN J.K.: Semen cryobanking for men with cancer — criteria change. Fertil. Steril., 1992, 58: 1024
STEPHENSON W.T., POIRIER S.M., RUBIN L., EINHORN LH.: Evaluation of reproductive capacity in germ cell tumor patients following treatment with cisplatin, etoposide and bleomycin. J. Clin. Oncol., 1995, 13: 2278–2280.
TRACHIL J.V., JEWM M.A.S., RIDER W.D.: The effects of cancer and cancer therapy on male fertility. J. Urol., 1981, 126: 141
VAN DER KOLK B.M., MULDER N.H., MANTINGH A. et al.: Children born after their fathers had been treated with chemotherapy for testicular cancer. Eur. J. Obstet. Gynecol. & Reprod. Biol., 1990, 34: 167
VELEZ DE LA CALLE J.F., BAUCHE F., JEGOU B.: Protection de la fertilité mâle lors des traitements anticancéreux: l’expérience animale. Prog. Urol., 1992, 2: 1
WARD J.A., ROBINSON J., FURR B.J. et al.: Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist. Cancer Res., 1990, 568–574.